Actively Recruiting
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
Led by University Hospital, Rouen · Updated on 2026-02-06
100
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the prevalence of positive anti BP180 and/or anti BP230 serology in the serum of patients with chronic and diffuse pruritus for at least 1 month under immunotherapy and in the absence of obvious pruritic dermatosis (e.g. scabies, contact eczema...).
CONDITIONS
Official Title
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient currently receiving immunotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab) as monotherapy or in combination OR patient who has received immunotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab) as monotherapy or in combination within the last 6 months.
- Patients with chronic (> 1 month) diffuse pruritus, which started after the start of immunotherapy and in the absence of an obvious pruritic dermatosis.
- Woman of childbearing age with effective contraception (estrogen-progestin or intrauterine device or tubal ligation) for 1 month (negative urine/blood pregnancy test) or postmenopausal woman with confirmed diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit).
- Adult patient.
- Patient having read and understood the information letter and signed the consent form.
- Patient affiliated to a social security scheme
You will not qualify if you...
- Pruritus prior to immunotherapy.
- Bullous pemphigoid prior to immunotherapy.
- End-stage chronic renal failure (GFR < 15ml/min or dialysis).
- Clinical jaundice or total bilirubin > 34 �b5mol/L.
- Hepatic cholestasis.
- Diabetes mellitus complicated by diabetic neuropathy.
- History of polycythemia vera.
- History of Hodgkin's lymphoma.
- Iron deficiency anemia.
- Current treatment including DPP-4 inhibitors (vildagliptin, linagliptin).
- Treatment with systemic corticosteroids or immunosuppressants for more than one month.
- Pregnant or parturient or breastfeeding woman or absence of proven contraception.
- Person deprived of liberty by an administrative or judicial decision or person placed under legal safeguard / sub-tutorship or curatorship.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UHRouen
Rouen, France
Actively Recruiting
Research Team
V
Vivien HEBERT, MD
CONTACT
A
Armelle GUIDOTTI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here